ABL1 and acute lymphoblastic leukemia: Since the specific BCL2 inhibitor ABT-199 is now approved for CLL therapy [16], we first analyzed the ABT-199 half-maximal inhibitory concentrations (IC50) in several BCR-ABL-positive and -negative ALL cell lines (Fig. S1A).